Free Trial
NASDAQ:BBLG

Bone Biologics 5/14/2024 Earnings Report

Bone Biologics logo
$4.94 +0.17 (+3.56%)
Closing price 03:54 PM Eastern
Extended Trading
$5.08 +0.14 (+2.83%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bone Biologics EPS Results

Actual EPS
-$7.86
Consensus EPS
-$45.60
Beat/Miss
Beat by +$37.74
One Year Ago EPS
N/A

Bone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bone Biologics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bone Biologics' next earnings date is estimated for Friday, August 8, 2025, based on past reporting schedules.

Conference Call Resources

Bone Biologics Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
BBLG Continues Crucial Testing
See More Bone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bone Biologics and other key companies, straight to your email.

About Bone Biologics

Bone Biologics (NASDAQ:BBLG), a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

View Bone Biologics Profile

More Earnings Resources from MarketBeat